- Category: Neurocognitive Problems
- Published on Friday, 17 August 2012 00:00
- Written by Press Release
A set of compounds related to epicatechin, a flavonoid found in cocoa and green tea leaves that easily crosses the blood-brain barrier, can protect against brain cell injury and death caused by HIV proteins in the laboratory, researchers reported in the August 11, 2012, online edition of Journal of NeuroVirology.
While AIDS-related dementia has diminished since the advent of effective antiretroviral therapy, mild-to-moderate neurocognitive problems remain common in the aging population of people with HIV. Researchers have studied many compounds in the hope of finding agents that can help protect against neural damage due to HIV or other causes such as Alzheimer's disease.
Below is an edited excerpt from a press release issued by Springer, publisher of the Journal of NeuroVirology, describing the study and its findings.
Hope for Patients with HIV-associated Cognitive Impairment
Researchers discover compounds in green tea and chocolate may help reduce neurological complications linked to HIV
August 14, 2012 -- Current drug therapy for patients with HIV is unable to control the complete replication of the virus in the brain. The drugs therefore do not have any effect against the complications associated with neurocognitive impairment in patients with HIV. New research by Joseph Steiner and colleagues from Johns Hopkins University has discovered that a group of plant polyphenols known as catechins, which naturally occur in green tea and the seed of the cacao tree, may help in the prevention of these neurological complications. Their work is published online in Springer’s Journal of NeuroVirology.
Previous research has established the critical role of a protein called brain-derived neurotrophic factor (BDNF) in supporting the survival and growth of neurons in the brain. This protein is active in areas of the brain vital to learning, memory, and higher thinking. Patients with HIV have been found to have lower levels of BDNF in their brains than healthy individuals, suggesting that this could be directly responsible for the cognitive impairment suffered.
In their research, Steiner and colleagues analyzed the effects of 2000 compounds, containing both natural substances and FDA-approved drugs, on brain cells in the laboratory. They identified a series of compounds which had the potential to help protect neurons in the brain. Nine of these were related to epicatechin, which is found in cocoa and green tea leaves. Further screening and comparison with resveratrol, the antioxidant found in red wine, specifically identified epicatechin and epigallocatechin gallate (EGCG) as being the most effective at helping protect neurons by inducing production of BDNF.
Although the antioxidant activities of epicatechin and EGCG are well documented, the discovery that they could be responsible for inducing production of BDNF is an exciting advancement in this area. The fact that these compounds readily cross the blood-brain barrier further increases their therapeutic potential, as this is often a major stumbling block in the development of therapies directed at the brain. This provides hope for patients with HIV as there is currently no neuroprotective therapy available for patients with HIV-associated cognitive impairment.
The authors conclude: "Due to its simpler structure and more efficient blood-brain barrier penetration properties, epicatechin might be the best therapeutic candidate for neurodegenerative diseases. These include HIV-associated cognitive disorders where oxidative stress is an important pathophysiological mechanism."
Further research in patients with HIV is required to elucidate just how effective these naturally occurring compounds could be.
S Nath, M Bachani, D Harshavardhana, and JP Steiner. Catechins Protect Neurons against Mitochondrial Toxins and HIV Proteins via Activation of the BDNF Pathway. Journal of NeuroVirology. August 11, 2012 (Epub ahead of print).
Springer Science + Business Media.Hope for patients with HIV-associated cognitive impairment. Press release. August 14, 2012.